BACKGROUND Non-vitamin K oral anticoagulants (NOACs) do not require routine laboratory monitoring. However, laboratory measurement may be desirable in special situations and populations.
agents collectively as non-vitamin K oral anticoagulants (NOACs) in this paper. Synonymous terms preferred by other researchers include direct-acting oral anticoagulant agents and new, novel, or targetspecific oral anticoagulant agents (1) .
Unlike warfarin and other vitamin K antagonists (VKAs), the NOACs are administered in fixed doses and do not require routine laboratory monitoring (2) (3) (4) .
However, measurement of their anticoagulant activity may be desirable in special clinical settings such as bleeding; the pre-operative state; breakthrough thrombosis; and suspected overdose, noncompliance, or drug interactions and in certain populations, including those with extremes in body weight and in the elderly and patients with renal insufficiency in whom there is a risk of drug accumulation.
Assessment of anticoagulant effect may also be important in patients with AF presenting with acute ischemic stroke before administration of thrombolytic therapy (5) .
Numerous studies on use of coagulation assays for measurement of NOAC activity have been published recently, although a systematic review has not been undertaken. The objective of our analysis was to summarize current evidence regarding laboratory measurement of NOAC anticoagulant activity and to provide evidence-based guidance to practicing cardiologists on the interpretation of coagulation tests in NOAC-treated patients. STUDY SELECTION. Articles were examined, first by title and abstract and then by review of the complete paper as indicated. Additional articles were sought by reviewing bibliographies. Liquid chromatography/ tandem mass spectrometry (LC-MS/MS) is the reference method for measurement of the plasma concentration of NOACs (6) . Studies 
METHODS

Laboratory Testing of Anticoagulants
With Persistent Atrial Fibrillation) study, the range (5th to 95th percentile) in peak and trough concentrations in patients taking 150 mg twice daily was 64 to 443 ng/ml and 31 to 225 ng/ml, respectively (9,10). Our literature search yielded 160 articles. Nine additional references were identified from bibliographies. A total of 152 articles were excluded: 135 did not report an original research study, 14 did not report drug levels measured by LC-MS/MS, and 3 were published as abstracts only.
S t u d y s e l e c t i o n .
The remaining 17 articles (11-27) met eligibility criteria ( Figure 1) . Eligible studies were collectively conducted in 9 different countries across a range of dabigatran concentrations from 0 to 1,886 ng/ml.
Only 4 studies used ex vivo plasma from dabigatrantreated patients; the remainder involved ex vivo healthy volunteer plasma or normal plasma spiked in vitro with dabigatran as the test material ( Table 2) .
A c t i v a t e d p a r t i a l t hr o m b o p l a s t i n t i m e . Twelve eligible studies reported a relationship between the activated partial thromboplastin time (APTT) and dabigatran levels. Three used ex vivo patient Laboratory Testing of Anticoagulants Commercial APTT reagents differ widely in their sensitivity to dabigatran. The APTT of plasma spiked with dabigatran 120 ng/ml ranged from 26.0 to 91.9 s in a cross-validation study of 9 different APTT methods (27) . These findings suggest that coagulation laboratories should perform dose-response studies using calibration standards to determine the sensitivity of their particular APTT method to dabigatran and communicate the results to clinicians. The least sensitive reagents required a dabigatran concentration of approximately 400 ng/ml to produce a 2-fold prolongation in the APTT over control (19) . The APTT may not be prolonged in the presence of typical on-therapy trough levels ( Table 1) , particularly if a relatively insensitive reagent is used. In a study of ex vivo plasma from patients taking dabigatran 150 mg twice daily, 18% of participants had a normal APTT at trough (25) . In another study of patients with AF, some samples had an APTT within the normal range despite dabigatran concentrations as high as 60 ng/ml (23) . ng/ml were beyond the POC system's limit of detection (22) . Table 2 ). The TT (in unmodified form) was inordinately sensitive in both ex vivo and in vitro studies.
Depending on the reagent, dabigatran concentrations of as little as 25 and up to 150 ng/ml exceeded the limits of detection (15) (16) (17) 28) .
D i l u t e T T . In the dilute TT assay, the excessive sensitivity of the TT is overcome by diluting the plasma sample (21) . Seven studies reported a relationship between the dilute TT and dabigatran concentration ( in vitro and ex vivo studies. The lower limit of detection according to the manufacturer is 50 ng/ml (21) . Two studies determined the assay to be less accurate and more variable at concentrations below 50 to 100 ng/ml (15, 21) . The dilute TT is currently not widely available; in a recent survey in Australia and New Zealand, only 9 of 592 laboratories reported using it (29) . Six studies reported a relationship between ECT and dabigatran levels ( Table 2 ). Both in vitro and ex vivo studies demonstrated a high degree of linearity, with R 2 values ranging between 0.92 and 1.00.
Loss of linearity was observed in 2 studies at dabigatran levels in excess of 470 to 500 ng/ml (17, 19) . A relationship between ECA and drug levels was reported in 4 studies ( Table 2) . The relationship was linear, with R 2 values of 0.94 to 0.99 in in vitro and ex vivo samples. One study identified greater variability at dabigatran concentrations <50 ng/ml (23) .
The ECT and ECA are hampered by lack of standardization, variability in sensitivity to dabigatran among different lots of ecarin, and limited availability (17, 20) . proved insensitive to lower concentrations of dabigatran. In an ex vivo study, the ACT was normal in 40% of trough samples despite on-therapy dabigatran levels (25) .
RIVAROXABAN. Rivaroxaban is an oral inhibitor of free and clot-associated factor Xa through reversible, competitive interactions with its active site (30) .
Bioavailability following oral administration is dose dependent (80% to 100% following a 10-mg dose;
66% following a 20-mg dose). It is highly bound to plasma proteins (>90%) (31); plasma levels peak 2 to 4 h following oral administration (32, 33) . Partially excreted by the kidneys (36%), rivaroxaban has a half-life of 6 to 13 h depending on dose and age (31-35). Table 1 shows expected peak and trough plasma concentrations in patients with AF treated with 20 mg daily (36) . Laboratory Testing of Anticoagulants on PT. Typical trough (41 to 60 ng/ml) and peak (219 to 305 ng/ml) concentrations increased PT by 6% to 19% and 50% to 135%, respectively (27, 38, 42, 47) .
Assay sensitivity varied significantly among thromboplastin reagents. Interassay variability was reduced by use of an international sensitivity index specific for rivaroxaban but not by conversion to an INR used for monitoring VKA therapy (38, 42) . These observations suggest that coagulation laboratories should perform dose-response studies using calibration standards to determine the sensitivity of their particular PT method for rivaroxaban and communicate the results to clinicians.
A c t i v a t e d p a r t i a l t h r o m b o p l a s t i n t i m e . Five
studies evaluated the effect of rivaroxaban on APTT ( Table 3) . Whereas rivaroxaban prolonged APTT in a dose-dependent manner, the overall relationship between rivaroxaban concentration and APTT prolongation was nonlinear, with studies reporting conflicting data regarding the concentration ranges over which nonlinearity was most pronounced (27, 41, 45) . Similar to PT results, there was significant variability among reagents and among individual laboratories in a multicenter study (27, 45) . Hillarp et al. (41) reported that the APTT assay was insensitive at the lowest drug level studied (25 ng/ml).
A n t i -X a a c t i v i t y . Ten studies assessed the effect of rivaroxaban on anti-Xa activity ( Table 3 ). In general, the studies showed a linear, concentrationdependent relationship between rivaroxaban concentration and anti-Xa activity over a wide range of concentrations (e.g., 20 to 660 ng/ml) when they were measured using a standard curve generated with rivaroxaban calibrators and controls with R 2 values ranging from 0.95 to 1.00 (39, 43, 44, 49, 50) . The correlation was less robust at concentrations <100 ng/ml (49 (45) . In a multicenter study, both intralaboratory and interlaboratory precision were satisfactory except at the lower limit of detection (20 ng/ml); use of a centrally distributed reagent reduced interlaboratory variability (46) .
Mathematical modeling also decreased interassay variability resulting from different sensitivities of individual reagents to rivaroxaban (40) . When commercial anti-Xa assays were used with unfractionated or low-molecular-weight heparin (LMWH) calibrators (rather than rivaroxaban calibrators), the relationship remained linear up to a rivaroxaban concentration of 500 ng/ml (38, 41) . Table 4) . For the 2 studies that used ex vivo plasma, the relationship was linear in one (37) and curvilinear in the other (55) . Correlation was modest, with R 2 values of 0.36 and 0.41, respectively.
Across in vitro and ex vivo samples and for a variety
of reagents, the PT was inadequately sensitive to apixaban, not only below, but also above the expected trough concentration of 50 ng/ml. Table 3) , which was measured using 10 different APTT reagents in normal plasma samples spiked with 10 different concentrations of apixaban. The sensitivity of the APTT was unacceptably low; all assays yielded a ratio of 1.1 times control when the spiked apixaban concentration was 100 ng/ml (i.e., twice the expected trough concentration).
A n t i -X a a c t i v i t y . Three studies compared anti-Xa activity measurements with the plasma concentration of apixaban ( Table 4 ). In 2 of the studies (37,54), ex vivo patient samples were used, whereas the third study (56) included only spiked samples of normal plasma. In general, the relationship was linear at all apixaban concentrations, with R 2 values ranging from 0.89 to 0.97. Available evidence suggests that an anti-Xa assay calibrated with LMWH standards will also correlate linearly with apixaban concentrations (37, 54) .
STUDY QUALITY. Assessment of study quality using QUADAS-2 criteria (7) highlighted several recurrent methodological concerns among eligible studies ( Table 5) . Many studies used in vitro samples or ex vivo samples from healthy controls rather than ex vivo patient samples. Concern about the applicability of these studies to clinical practice within the patient selection domain was judged to be high. Some studies examined assays not widely available to clinicians (e.g., ECA, ECT, dilute TT). Concern regarding applicability of these studies to clinical practice across the index test domain was judged to be high.
Because data correlating plasma NOAC levels and clinical outcomes are scarce, concern about the Anti-Xa -Anti-Xa -Suggestions for laboratory measurement of the anticoagulant activity of dabigatran, rivaroxaban, and apixaban are based on the clinical objective. Typical on-therapy drug levels are shown in Table 1 . Table 2 .
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